1. Home
  2. LCTX vs GFR Comparison

LCTX vs GFR Comparison

Compare LCTX & GFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCTX
  • GFR
  • Stock Information
  • Founded
  • LCTX 1990
  • GFR 2018
  • Country
  • LCTX United States
  • GFR Canada
  • Employees
  • LCTX N/A
  • GFR N/A
  • Industry
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • GFR
  • Sector
  • LCTX Health Care
  • GFR
  • Exchange
  • LCTX Nasdaq
  • GFR Nasdaq
  • Market Cap
  • LCTX 274.0M
  • GFR 318.9M
  • IPO Year
  • LCTX N/A
  • GFR N/A
  • Fundamental
  • Price
  • LCTX $1.21
  • GFR $5.07
  • Analyst Decision
  • LCTX Strong Buy
  • GFR
  • Analyst Count
  • LCTX 4
  • GFR 0
  • Target Price
  • LCTX $4.25
  • GFR N/A
  • AVG Volume (30 Days)
  • LCTX 1.5M
  • GFR 32.2K
  • Earning Date
  • LCTX 08-12-2025
  • GFR 08-06-2025
  • Dividend Yield
  • LCTX N/A
  • GFR N/A
  • EPS Growth
  • LCTX N/A
  • GFR N/A
  • EPS
  • LCTX N/A
  • GFR 2.05
  • Revenue
  • LCTX $10,914,000.00
  • GFR $516,308,125.00
  • Revenue This Year
  • LCTX N/A
  • GFR N/A
  • Revenue Next Year
  • LCTX $178.80
  • GFR $27.03
  • P/E Ratio
  • LCTX N/A
  • GFR $2.42
  • Revenue Growth
  • LCTX 76.43
  • GFR N/A
  • 52 Week Low
  • LCTX $0.37
  • GFR $3.81
  • 52 Week High
  • LCTX $1.31
  • GFR $8.16
  • Technical
  • Relative Strength Index (RSI)
  • LCTX 59.58
  • GFR 65.10
  • Support Level
  • LCTX $1.15
  • GFR $4.14
  • Resistance Level
  • LCTX $1.31
  • GFR $5.01
  • Average True Range (ATR)
  • LCTX 0.08
  • GFR 0.25
  • MACD
  • LCTX 0.01
  • GFR 0.06
  • Stochastic Oscillator
  • LCTX 70.59
  • GFR 98.85

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About GFR Greenfire Resources Ltd.

Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.

Share on Social Networks: